Publikasjoner - Legemiddelinteraksjoner
Avdeling for klinisk farmakologi
• Thu OK, Spigset O, Hellum B. Non-competitive inhibition of human CYP2C9 in vitro by a commercial Rhodiola rosea product. Pharmacol Res Perspect 2017; 5: e00324.
https://www.ncbi.nlm.nih.gov/pubmed/?term=28805981
• Landmark CJ, Svendsen T, Dinarevic J, Kufaas RF, Reimers A, Brodtkorb E, Baftiu A, Burns ML, Johannessen SI. The impact of pharmacokinetic interactions with eslicarbazepine acetate versus oxcarbazepine and carbamazepine in clinical practice. Ther Drug Monit. 2016; 38: 499-505.
https://www.ncbi.nlm.nih.gov/pubmed/27414974
• Reimers A. Hormone replacement therapy with estrogens may reduce lamotrigine serum concentrations: A matched case-control study. Epilepsia 2017; 58: e6-e9.
https://www.ncbi.nlm.nih.gov/pubmed/27805259
• Thu OKF, Spigset O, Nilsen OG, Hellum B. Effect of commercial Rhodiola rosea on CYP enyme activity in humans. Eur J Clin Pharmacol 2016; 72: 295-300.
http://www.ncbi.nlm.nih.gov/pubmed/?term=26613955
• Gjestad C, Westin AA, Skogvoll E, Spigset O. Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram and sertraline. Ther Drug Monit 2015; 37: 90-7.
http://www.ncbi.nlm.nih.gov/pubmed/?term=24887634